SCGB2A2 and Autoimmunity: Expression of mammaglobin A in normal tissues certainly limits its potential use as an immunotherapeutic target, due to concerns about autoimmune toxicity, particularly since autoimmunity is not a concern with other immunotherapeutic targets [38].